HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Omnibus appropriations signed

This article was originally published in The Rose Sheet

Executive Summary

President Bush signs H.J. Res. 2 on Feb. 20, providing federal government $397.4 bil. for FY 2003. House and Senate agreed to conference report Feb. 13. Budget provides $1 mil. in increased funding for OTC-related activity (1"The Rose Sheet" Feb. 10, 2003, In Brief)...

You may also be interested in...



FDA budget

President Bush's fiscal 2004 budget proposal calls for $1 mil. increase in funding for OTC-related activity, which would be used in part to "develop and work toward finalizing standards...for analgesic, antiseptic, laxative and sunscreen drug products for OTC use." Increase would boost OTC budget 10.6% to nearly $10.4 mil. and would be used to add seven full time equivalent OTC employees, bringing the total number to 69. Under the proposal, Center for Food Safety and Applied Nutrition spending would decrease 2.5% to $144.4 mil., but the decline would be offset by increased funding for field activities, which would grow 1.8% to $268.9 mil. FDA's total FY '04 budget request comes to almost $1.41 bil., up about 1.6% from the FY 2003 proposed funding level. Including user fees, the agency is requesting $1.71 bil., a 3.5% increase...

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

UsernamePublicRestriction

Register

RS011016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel